Sotera Health (NASDAQ:SHC) Earns Neutral Rating from Analysts at The Goldman Sachs Group

Investment analysts at The Goldman Sachs Group assumed coverage on shares of Sotera Health (NASDAQ:SHC - Get Free Report) in a report issued on Friday, Marketbeat reports. The firm set a "neutral" rating and a $14.00 price target on the stock. The Goldman Sachs Group's target price points to a potential upside of 6.63% from the stock's previous close.

Several other research firms also recently commented on SHC. Royal Bank of Canada reiterated an "outperform" rating and issued a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st. Citigroup boosted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Sotera Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.08.

Sotera Health Stock Up 1.2 %

Shares of SHC stock traded up $0.16 during trading hours on Friday, hitting $13.13. 988,391 shares of the company's stock traded hands, compared to its average volume of 1,712,090. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The stock's fifty day simple moving average is $14.96 and its two-hundred day simple moving average is $14.06. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44. The stock has a market cap of $3.72 billion, a price-to-earnings ratio of 52.52 and a beta of 1.96.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The company had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. During the same quarter in the previous year, the business earned $0.18 earnings per share. Sotera Health's revenue was up 8.5% compared to the same quarter last year. On average, analysts expect that Sotera Health will post 0.61 EPS for the current year.

Institutional Trading of Sotera Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. William Blair Investment Management LLC boosted its position in shares of Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company's stock valued at $13,430,000 after acquiring an additional 6,707 shares during the last quarter. Clearline Capital LP bought a new position in Sotera Health during the second quarter valued at $1,707,000. Maven Securities LTD bought a new position in Sotera Health during the third quarter valued at $1,670,000. First Pacific Advisors LP purchased a new position in shares of Sotera Health in the 2nd quarter worth $540,000. Finally, Darsana Capital Partners LP bought a new stake in shares of Sotera Health in the 2nd quarter worth about $29,074,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.